Page 151 - 南京医科大学学报自然科学版
P. 151
第42卷第1期 王鑫羊,夏添松. 循环肿瘤细胞在转移性乳腺癌中的应用[J].
2022年1月 南京医科大学学报(自然科学版),2022,42(01):142-146 ·145 ·
巨大的优势,在转移性乳腺癌患者中尤其明显。这 randomized phase Ⅲ JO21095 trial in Japanese patients
使得在疾病进展期间及治疗前后进行个体化纵向 with HER2⁃negative metastatic breast cancer[J]. Breast
监测肿瘤的生物学行为、评估肿瘤异质性成为可 Cancer Res Treat,2017,162(3):501-510
能。实时监测肿瘤的生物学特征有助于观察疾病 [9] CABEL L,BERGER F,COTTU P,et al. Clinical utility of
的进程和治疗反应,以便于调整后续的治疗方 circulating tumour cell⁃based monitoring of late⁃line che⁃
motherapy for metastatic breast cancer:the randomised
案。诚然,CTC 在无创性和可重复性方面拥有明
Circe01 trial[J]. Br J Cancer,2021,124(7):1207-1213
显的优势,但还需要更多的多中心、前瞻性研究来
[10] SPARANO J,O’NEILL A,ALPAUGH K,et al. Associa⁃
证实CTC在精准、合理地指导转移性乳腺癌患者的
tion of circulating tumor cells with late recurrence of es⁃
治疗选择、疗效评价及方案调整等方面的临床应用
trogen receptor⁃positive breast cancer:a secondary analy⁃
价值。
sis of a randomized clinical trial[J]. JAMA Oncol,2018,4
[参考文献] (12):1700-1706
[11] CRISTOFANILLI M,JY P,REUBEN J,et al. The clinical
[1] SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer
use of circulating tumor cells(CTCs)enumeration for stag⁃
statistics 2020:GLOBOCAN estimates of incidence and
ing of metastatic breast cancer(MBC):international ex⁃
mortality worldwide for 36 cancers in 185 countries[J].
pert consensus paper[J]. Crit Rev Oncol Hematol,2019,
CA Cancer J Clin,2021,71(3):209-249
134:39-45
[2] CRISTOFANILLI M,BUDD G T,ELLIS M J,et al. Circu⁃
[12] MUNZONE E,NOLÉ F,GOLDHIRSCH A,et al. Changes
lating tumor cells,disease progression,and survival in
of HER2 status in circulating tumor cells compared with
metastatic breast cancer[J]. New Engl J Med,2004,351
the primary tumor during treatment for advanced breast
(8):781-791
cancer[J]. Clin Breast Cancer,2010,10(5):392-397
[3] PIERGA J Y,HAJAGE D,BACHELOT T,et al. High in⁃
[13] ONSTENK W,SIEUWERTS A M,WEEKHOUT M,et al.
dependent prognostic and predictive value of circulating
Gene expression profiles of circulating tumor cells versus
tumor cells compared with serum tumor markers in a
large prospective trial in first⁃line chemotherapy for meta⁃ primary tumors in metastatic breast cancer[J]. Cancer
Lett,2015,362(1):36-44
static breast cancer patients[J]. Ann Oncol,2012,23
[14] AGELAKI S,DRAGOLIA M,MARKONANOLAKI H,et
(3):618-624
[4] GIORDANO A,GIULIANO M,DE LAURENTIIS M,et al. Phenotypic characterization of circulating tumor cells
in triple negative breast cancer patients[J]. Oncotarget,
al. Circulating tumor cells in immunohistochemical sub⁃
types of metastatic breast cancer:lack of prediction in 2017,8(3):5309-5322
HER2⁃positive disease treated with targeted therapy[J]. [15] REIJM E A,SIEUWERTS A M,SMID M,et al. An 8⁃gene
Ann Oncol,2012,23(5):1144-1150 mRNA expression profile in circulating tumor cells pre⁃
[5] PAOLETTI C,MIAO J,DOLCE E M,et al. Circulating tu⁃ dicts response to aromatase inhibitors in metastatic breast
mor cell clusters in patients with metastatic breast cancer: cancer patients[J]. BMC Cancer,2016,16:123
a SWOG S0500 translational medicine study[J]. Clin [16] MOSTERT B,SIEUWERTS A M,KRAAN J,et al. Gene
Cancer Res,2019,25(20):6089-6097 expression profiles in circulating tumor cells to predict
[6] SMERAGE J B,BARLOW W E,HORTOBAGYI G N,et prognosis in metastatic breast cancer patients[J]. Ann
al. Circulating tumor cells and response to chemotherapy Oncol,2015,26(3):510-516
in metastatic breast cancer:SWOG S0500[J]. J Clin On⁃ [17] MENG S,TRIPATHY D,SHETE S,et al. HER⁃2 gene
col,2014,32(31):3483-3489 amplification can be acquired as breast cancer progresses
[7] BIDARD F C,JACOT W,KIAVUE N,et al. Efficacy of [J]. Proc Natl Acad Sci U S A,2004,101(25):9393-
circulating tumor cell count ⁃ driven vs. clinician ⁃ driven 9398
first ⁃ line therapy choice in hormone receptor ⁃ positive, [18] DOI T,SHITARA K,NAITO Y,et al. Safety,pharmacoki⁃
ERBB2⁃negative metastatic breast cancer:the STIC CTC netics,and antitumour activity of trastuzumab deruxtecan
randomized clinical trial[J]. JAMA Oncol,2021,7(1): (DS⁃8201),a HER2⁃targeting antibody⁃drug conjugate,
34-41 in patients with advanced breast and gastric or gastro⁃oe⁃
[8] IWATA H,MASUDA N,YAMAMOTO D,et al. Circulat⁃ sophageal tumours:a phase 1 dose⁃escalation study[J].
ing tumor cells as a prognostic marker for efficacy in the Lancet Oncol,2017,18(11):1512-1522